Clinical Trial

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Change of registrant
Summary
This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-07; most recent amendment 2026-02-10.
Status change: Recruiting → Terminated 2026-02-10
Status change: Not Yet Recruiting → Recruiting 2025-06-27
Trial Details
NCT Number NCT06965309
Lead Sponsor Shenzhen MagicRNA Biotechnology Co., Ltd
Collaborators: Shanghai General Hospital (Songjiang Branch)
Conditions Refractory Myasthenia Gravis
Enrollment 9 participants
Start Date 2026-01-19
Primary Completion 2026-02-11 (estimated)
Study Completion 2026-02-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-12